DiabetesDyslipidaemiaHypertension and CV risk
04.03.2026
VIDEO | Why Ethical Narratives Matter
2
VIDEO | Why Ethical Narratives Matter
Discover more articles, guidelines and events.
CPD ARTICLE | ADD2Dia: Real-World Clinical Effectiveness of Adding a Sodium-Glucose Cotransporter 2 Inhibitor to Gliclazide-Based Therapy in Type 2 Diabetes
CPDDiabetes
19.02.2026
CPD ARTICLE | ADD2Dia: Real-World Clinical Effectiveness of Adding a Sodium-Glucose Cotransporter 2 Inhibitor to Glic...
1
18
CPD ARTICLE | One Pill or Many?
CPDDiabetesHypertension and CV riskPatient Awareness
17.02.2026
CPD ARTICLE | One Pill or Many?
46
CPD ARTICLE | Outcomes of People with Type 2 Diabetes using Sulfonylureas versus Other Non-Insulin Antidiabetic Agents during Ramadan: The Diabetes and Ramadan (DaR) Global Surveys.
CPDDiabetes
11.02.2026
CPD ARTICLE | Outcomes of People with Type 2 Diabetes using Sulfonylureas versus Other Non-Insulin Antidiabetic Agent...
27
VIDEO | Double Risk, Double Trouble
Hypertension and CV risk
06.02.2026
VIDEO | Double Risk, Double Trouble
5
VIDEO | Conquering the dual threat of hypertension & dyslipidaemia with a polypill
DyslipidaemiaHypertension and CV risk
06.02.2026
VIDEO | Conquering the dual threat of hypertension & dyslipidaemia with a polypill
10
VIDEO | Overwhelmed with choice or not really?
CPDDiabetes
13.11.2025
VIDEO | Overwhelmed with choice or not really?
3
81
VIDEO | A Triple SPC approach to cardiovascular management
CPDHypertension and CV risk
13.11.2025
VIDEO | A Triple SPC approach to cardiovascular management
1
45
VIDEO | A Complimentary Strategy – A Polypill Approach for Cardiovascular Health
CPDDyslipidaemiaHypertension and CV risk
03.11.2025
VIDEO | A Complimentary Strategy – A Polypill Approach for Cardiovascular Health
30
VIDEO | Who’s responsibility is Adherence
CPDDiabetesDyslipidaemiaHypertension and CV risk
20.10.2025
VIDEO | Who’s responsibility is Adherence
55